Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga

• Autori principali: Ana G. Lopes (Autore), Marianlie Navarro (Autore), Carmem Botelho (Autore), Maria J. Guimarães (Autore), Catarina Cerqueira (Autore), Joana Gomes (Autore), Celeste Brito (Autore)
• Natura: Libro
• Pubblicazione: Sociedade Portuguesa de Dermatologia e Venereologia, 2022-10-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine. Few data are available to help predict the response to omalizumab in the Portuguese population. Objective: Characterize the populatio...